A Phase 3 interventional study of JW0104+C2402 and JW0104+C2403 in Hypertension and Dyslipidemia, sponsored by JW Pharmaceutical. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-09-09.
Sponsored by JW Pharmaceutical · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 353 studies in Hypertension with a site in Korea, Republic of — 30 open to participants now, 41 under way, 11 of them phase 3. Hypertension · Korea, Republic of.
Among the 353 studies in Hypertension with a site in Korea, Republic of, this one is the 116th largest by planned enrollment of the 304 interventional ones that give a count, is one of 15 that started in 2024, is one of 92 in phase 3, reaches primary completion later than 20 of the 40 other live ones, and was the 322nd registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →30 of the 353 studies in Hypertension with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Korea United Pharm. Inc. · Sites in Korea, Republic of
Ages 19–54 · Healthy volunteers
Hanmi Pharmaceutical Company Limited · Sites in Korea, Republic of
Hanlim Pharm. Co., Ltd. · Sites in Korea, Republic of
Ages 19+
Keimyung University Dongsan Medical Center · Sites in Korea, Republic of
Ages 19+
Korea University Anam Hospital · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
353 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 102 · Phase 2 22 · Phase 3 93 · Phase 4 60
First in 2003; this study’s year is marked. 15 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 162 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 110 across the 304 interventional studies, 2,000 across the 47 observational. Of the 277 that completed or were terminated, 41 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
283 of 353 have an industry lead sponsor. The 10 most frequent:
JW Pharmaceutical is the lead sponsor of 77 studies on the registry; 6 are open to participants now.
JW Pharmaceutical has 5 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
5 of the studies in Hypertension with a site in Korea, Republic of that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT07660796Phase 3Hanmi Pharmaceutical Company LimitedA Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension | 2027-10-30 |
| NCT07901114AJU Pharm Co., Ltd.A Bioequivalence and Safety Study of AJU-C719 and C719R in Healthy Adult Volunteers | 2026-12 |
| NCT07465549Korea University Anam HospitalCART BP Pro-Guided Blood Pressure Management for Uncontrolled Hypertension | 2026-12-31 |
| NCT07784621Huons Co., Ltd.A Phase 1 Clinical Trial to Evaluate the Safety and the Pharmacokinetic Drug-Drug Interaction Between HUC2A-752-A and HUC2A-752-B in Healthy Adults | 2027-02 |
Add all 5 to your calendar (.ics) → With an account.
Among the 353 studies in Hypertension with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients with Hypertension and Dyslipidemia
To evaluate the efficacy and safety of co-administration of JW0104+C2402 in comparison with co-administration of JW0104+C2403 or C2402 alone in patients with hypertension and dyslipidemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
JW0104+C2402, 8 weeks, QD (Quaque Die)
Drug: JW0104+C2402
JW0104+C2403, 8 weeks, QD
Drug: JW0104+C2403
C2402, 8 weeks, QD
Drug: C2402
For 8 weeks(PO (Per Oral), QD)
Also known as: NA (Not Applicable)
For 8 weeks(PO, QD)
Also known as: NA (Not Applicable)
For 8 weeks(PO, QD)
Also known as: NA (Not Applicable)
Change from baseline in msSBP (Systolic Blood Pressure)
Check msSBP
Time frame: week 8
Percent change from baseline in LDL-C (Low-Density Lipoprotein Cholesterol)
Check LDL-C
Time frame: week 8
change from baseline in msSBP
Check msSBP
Time frame: week 4
Change and percent change from baseline in LDL-C
Check LDL-C
Time frame: week 4
Started Dec 2024 (actual). Primary completion is estimated for Apr 2026, 16 months after the start.
Of 95 industry-sponsored phase 3 interventional studies under Hypertension, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's planned 16 months is below that.
Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.